Skip to main content
Top
Published in: BMC Health Services Research 1/2007

Open Access 01-12-2007 | Research article

Impact of prescription size on statin adherence and cholesterol levels

Authors: Holly A Batal, Mori J Krantz, Rita A Dale, Phillip S Mehler, John F Steiner

Published in: BMC Health Services Research | Issue 1/2007

Login to get access

Abstract

Background

Therapy with 3-Hydroxy-3-methylglutaryl Co-enzyme A reductase inhibitors (statins) improve outcomes in a broad spectrum of patients with hyperlipidemia. However, effective therapy requires ongoing medication adherence; restrictive pharmacy policies may represent a barrier to successful adherence, particularly among vulnerable patients. In this study we sought to assess the relationship between the quantity of statin dispensed by the pharmacy with patient adherence and total cholesterol.

Methods

We analyzed a cohort of 3,386 patients receiving more than one fill of statin medications through an integrated, inner-city health care system between January 1, 2000 and December 31, 2002. Our measure of adherence was days of drug acquisition divided by days in the study for each patient, with adequate adherence defined as ≥ 80%. Log-binomial regression was used to determine the relative risk of various factors, including prescription size, on adherence. We also assessed the relationship between adherence and total cholesterol using multiple linear regression.

Results

After controlling for age, gender, race, co-payment, comorbidities, and insurance status, patients who obtained a majority of fills as 60-day supply compared with 30-day supply were more likely to be adherent to their statin medications (RR 1.41, 95% CI 1.28–1.55, P < 0.01). We found that statin non-adherence less than 80% was predictive of higher total serum cholesterol by 17.23 ± 1.64 mg/dL (0.45 ± 0.04 mmol/L).

Conclusion

In a healthcare system serving predominantly indigent patients, the provision of a greater quantity of statin medication at each prescription fill contributes to improved adherence and greater drug effectiveness.
Literature
1.
go back to reference Haynes RB, Montague P, Oliver T, McKibbon KA, Brouwers MC, Kanani R: Interventions for helping patients to follow prescriptions for medications (Cochrane Review). The Cochrane Library. 2001, Oxford: Update Software, 4 Haynes RB, Montague P, Oliver T, McKibbon KA, Brouwers MC, Kanani R: Interventions for helping patients to follow prescriptions for medications (Cochrane Review). The Cochrane Library. 2001, Oxford: Update Software, 4
2.
go back to reference Adherence to long-term therapies: evidence for action. 2003, World Health Organization Adherence to long-term therapies: evidence for action. 2003, World Health Organization
3.
go back to reference Psaty BM, Koepsell TD, Wagner EH, LoGerfo JP, Inui TS: The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. JAMA. 1990, 263: 1653-1657. 10.1001/jama.263.12.1653.CrossRef Psaty BM, Koepsell TD, Wagner EH, LoGerfo JP, Inui TS: The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. JAMA. 1990, 263: 1653-1657. 10.1001/jama.263.12.1653.CrossRef
4.
go back to reference Maronde RF, Chan LS, Larsen FJ, Starandberg LR, Laventurier MF, Sullivan SR: Underutilization of antihypertensive drugs and associated hospitalization. Med Care. 1989, 27: 1159-1166. 10.1097/00005650-198912000-00007.CrossRef Maronde RF, Chan LS, Larsen FJ, Starandberg LR, Laventurier MF, Sullivan SR: Underutilization of antihypertensive drugs and associated hospitalization. Med Care. 1989, 27: 1159-1166. 10.1097/00005650-198912000-00007.CrossRef
5.
go back to reference Cramer JA, Silverman S: Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med. 2006, 119: 12S-17S. 10.1016/j.amjmed.2005.12.018.CrossRef Cramer JA, Silverman S: Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med. 2006, 119: 12S-17S. 10.1016/j.amjmed.2005.12.018.CrossRef
6.
go back to reference Tamblyn R, Laprise R, Hanley RA: Adverse events associated with prescription drug cost-sharing among poor and elderly patients. JAMA. 2001, 285: 421-429. 10.1001/jama.285.4.421.CrossRef Tamblyn R, Laprise R, Hanley RA: Adverse events associated with prescription drug cost-sharing among poor and elderly patients. JAMA. 2001, 285: 421-429. 10.1001/jama.285.4.421.CrossRef
7.
go back to reference McCombs JS, Wyatt RA, Adlis SA: Comparison of patients' compliance with prescribed oral and inhaled asthma medications. Arch Intern Med. 1994, 154: 1349-1352. 10.1001/archinte.154.12.1349.CrossRef McCombs JS, Wyatt RA, Adlis SA: Comparison of patients' compliance with prescribed oral and inhaled asthma medications. Arch Intern Med. 1994, 154: 1349-1352. 10.1001/archinte.154.12.1349.CrossRef
8.
go back to reference Steiner JF, Robbins LJ, Roth SC, Hammond WS: The effect of prescription size on acquisition of maintenance medications. J Gen Intern Med. 1993, 8: 306-310. 10.1007/BF02600143.CrossRef Steiner JF, Robbins LJ, Roth SC, Hammond WS: The effect of prescription size on acquisition of maintenance medications. J Gen Intern Med. 1993, 8: 306-310. 10.1007/BF02600143.CrossRef
9.
go back to reference Executive summary of the third report on the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001, 285: 2486-97. 10.1001/jama.285.19.2486. Executive summary of the third report on the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001, 285: 2486-97. 10.1001/jama.285.19.2486.
10.
go back to reference Steiner JF, Prochazka AV: The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997, 50: 105-116. 10.1016/S0895-4356(96)00268-5.CrossRef Steiner JF, Prochazka AV: The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997, 50: 105-116. 10.1016/S0895-4356(96)00268-5.CrossRef
11.
go back to reference Christensen DB, Williams B, Goldberg HI, Martin DP, Engelberg R, LoGerfo JP: Assessing compliance to antihypertensive medications using computer-based pharmacy records. Med Care. 1997, 35: 1164-70. 10.1097/00005650-199711000-00008.CrossRef Christensen DB, Williams B, Goldberg HI, Martin DP, Engelberg R, LoGerfo JP: Assessing compliance to antihypertensive medications using computer-based pharmacy records. Med Care. 1997, 35: 1164-70. 10.1097/00005650-199711000-00008.CrossRef
12.
go back to reference Wei L, Wang J, Thompson P, Wong S, Struthers AD, MacDonald TM: Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart. 2002, 88: 229-233. 10.1136/heart.88.3.229.CrossRef Wei L, Wang J, Thompson P, Wong S, Struthers AD, MacDonald TM: Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart. 2002, 88: 229-233. 10.1136/heart.88.3.229.CrossRef
13.
go back to reference Blackburn DF, Dobson RT, Blackburn JL, Wilson TW: Cardiovascular morbidity associated with nonadherence to statin therapy. Pharmacotherapy. 2005, 25: 1035-1043. 10.1592/phco.2005.25.8.1035.CrossRef Blackburn DF, Dobson RT, Blackburn JL, Wilson TW: Cardiovascular morbidity associated with nonadherence to statin therapy. Pharmacotherapy. 2005, 25: 1035-1043. 10.1592/phco.2005.25.8.1035.CrossRef
14.
go back to reference Chapman RH, Benner JS, Petrilla AA: Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005, 165: 1147-1152. 10.1001/archinte.165.10.1147.CrossRef Chapman RH, Benner JS, Petrilla AA: Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005, 165: 1147-1152. 10.1001/archinte.165.10.1147.CrossRef
15.
go back to reference Clark DO, Von Korff M, Saunders K, Baluch WM, Simon GE: A chronic disease score with empirically derived weights. Med Care. 1995, 33: 783-795. 10.1097/00005650-199508000-00004.CrossRef Clark DO, Von Korff M, Saunders K, Baluch WM, Simon GE: A chronic disease score with empirically derived weights. Med Care. 1995, 33: 783-795. 10.1097/00005650-199508000-00004.CrossRef
16.
go back to reference Deddens JA, Petersen MR: Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol. 2004, 159: 213-214. 10.1093/aje/kwh022.CrossRef Deddens JA, Petersen MR: Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol. 2004, 159: 213-214. 10.1093/aje/kwh022.CrossRef
17.
go back to reference Osterberg L, Blaschke T: Adherence to medication. N Engl J Med. 2005, 353: 487-497. 10.1056/NEJMra050100.CrossRef Osterberg L, Blaschke T: Adherence to medication. N Engl J Med. 2005, 353: 487-497. 10.1056/NEJMra050100.CrossRef
18.
go back to reference Nelson K, Norris K, Mangione CM: Disparities in the diagnosis and pharmacologic treatment of high serum cholesterol by race and ethnicity. Arch Intern Med. 2002, 162: 929-935. 10.1001/archinte.162.8.929.CrossRef Nelson K, Norris K, Mangione CM: Disparities in the diagnosis and pharmacologic treatment of high serum cholesterol by race and ethnicity. Arch Intern Med. 2002, 162: 929-935. 10.1001/archinte.162.8.929.CrossRef
19.
go back to reference Safford M, Eaton L, Hawley G: Disparities in use of lipid-lowering medications among people with type 2 diabetes mellitus. Arch Intern Med. 2003, 163: 922-928. 10.1001/archinte.163.8.922.CrossRef Safford M, Eaton L, Hawley G: Disparities in use of lipid-lowering medications among people with type 2 diabetes mellitus. Arch Intern Med. 2003, 163: 922-928. 10.1001/archinte.163.8.922.CrossRef
20.
go back to reference Massing MW, Foley KA, Carter-Edwards L, Sueta CA, Alexander CM, Simpson RJ: Disparities in lipid management for African American and Caucasians with coronary artery disease: a national cross-sectional study. BMC Cardiovascular Disorders. 2004, 4: 15-10.1186/1471-2261-4-15. doi:10.1186/1471-2261-4-15CrossRef Massing MW, Foley KA, Carter-Edwards L, Sueta CA, Alexander CM, Simpson RJ: Disparities in lipid management for African American and Caucasians with coronary artery disease: a national cross-sectional study. BMC Cardiovascular Disorders. 2004, 4: 15-10.1186/1471-2261-4-15. doi:10.1186/1471-2261-4-15CrossRef
21.
go back to reference Hendrix KH, Riehle JE, Egan BM: Ethnic, gender, and age-related differences in treatment and control of dyslipidemia in hypertensive patients. Ethn Dis. 2005, 15: 11-16.PubMed Hendrix KH, Riehle JE, Egan BM: Ethnic, gender, and age-related differences in treatment and control of dyslipidemia in hypertensive patients. Ethn Dis. 2005, 15: 11-16.PubMed
22.
go back to reference Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J: Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002, 288: 455-461. 10.1001/jama.288.4.455.CrossRef Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J: Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002, 288: 455-461. 10.1001/jama.288.4.455.CrossRef
23.
go back to reference Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM: Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med. 2004, 19: 638-645. 10.1111/j.1525-1497.2004.30516.x.CrossRef Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM: Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med. 2004, 19: 638-645. 10.1111/j.1525-1497.2004.30516.x.CrossRef
24.
go back to reference Schultz JS, O'Donnell JC, McDonough KL, Sasane R, Meyer J: Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population. Am J Manag Care. 2005, 11: 306-312.PubMed Schultz JS, O'Donnell JC, McDonough KL, Sasane R, Meyer J: Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population. Am J Manag Care. 2005, 11: 306-312.PubMed
25.
go back to reference Grundy SM, Cleeman JI, Bairey CN: Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation. 2004, 110: 227-239. 10.1161/01.CIR.0000133317.49796.0E.CrossRef Grundy SM, Cleeman JI, Bairey CN: Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation. 2004, 110: 227-239. 10.1161/01.CIR.0000133317.49796.0E.CrossRef
Metadata
Title
Impact of prescription size on statin adherence and cholesterol levels
Authors
Holly A Batal
Mori J Krantz
Rita A Dale
Phillip S Mehler
John F Steiner
Publication date
01-12-2007
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2007
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/1472-6963-7-175

Other articles of this Issue 1/2007

BMC Health Services Research 1/2007 Go to the issue